Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.939959
Abstract: Background Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), who are at the risk of developing bone metastasis. During bone metastasis, tumor cells release factors… read more here.
Keywords: bone loss; effect ceritinib; osteoclast formation; ceritinib ... See more keywords